Clinical experience with Zarzio® in Europe: what have we learned? - Wikidata - awgldk - TriplyDB

Clinical experience with Zarzio® in Europe: what have we learned?

Clinical experience with Zarzio® in Europe: what have we learned?

http://www.wikidata.org/entity/Q38125609

about

The changing landscape of biosimilars in rheumatology Clinical considerations for the development of biosimilars in oncology Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?A systematic review of geographical variation in access to chemotherapy Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.G-CSF: filgrastim, lenograstim and biosimilars.Biosimilars for the management of rheumatoid arthritis: economic considerations.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.Biosimilar medicines - Review.Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.Drug tendering: drug supply and shortage implications for the uptake of biosimilars Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars Biosimilar uptake by British local formularies: a cross sectional study.MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.Extrapolation concept at work with biosimilar: a decade of experience in oncology.Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product The role of biosimilars in value-based oncology care Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinati Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

P2860

Q26766515-BDEA9110-15EC-4B06-997D-DDDE710C61BD Q28081768-856326B2-D15C-4C7B-9F32-4631850B9602 Q35192785-065905D7-9E9D-4ED0-90BD-438240ED85BD Q35547653-466A71BB-AA59-465F-A8CB-5D57DFCAE57B Q35835005-FF554BEE-8801-4114-BE5A-661D603916AC Q35882864-263CE0F7-078B-4ACA-911A-A038BEA57851 Q35922123-1DB973C1-2B4B-4266-9AEB-F9D5FBB35AE0 Q36000209-8265A954-F3C3-4967-BFA6-D86D01486769 Q36723952-54675152-9773-4292-BECD-8A82A51ECFCE Q37731321-6F777299-A882-4E91-A525-B8E31E7A4FEC Q38193590-D8FF5BEF-4B78-4E16-B692-1892AE06DA1A Q38202661-ADC84AF8-0151-41A8-820E-F3476755587D Q38591281-AB0CF24C-C5B2-45BA-8EDD-29A970484E41 Q38592363-4251BCB3-0FC5-4EC6-9A8F-893410F0129D Q38643555-FB348B2E-C345-4D5E-9FBA-F42A663D0207 Q38707629-41C4AFDD-E3B2-44B1-855B-F70F170D84D0 Q38833786-110B7EB8-CE6E-4AC7-800F-91A3CBEFD541 Q38889400-273A95A2-A021-4907-9087-5E9CAA59D9E0 Q38893192-3C60345B-EB62-47A4-B7EF-2AC35570782E Q39385304-D1240C4C-7FAF-4C9F-9570-6544B7FA8ACC Q40141879-73A027C9-3C06-476B-B441-8C9A1275C363 Q42363042-1857B8C3-EBB6-4536-9597-5F423BD5A32D Q42370596-D6A01C17-2388-45DF-87CB-6565C1B0F67F Q42385440-051C3B10-6E28-42D0-82FE-BD1DC27B624C Q47142044-29B17D71-F68B-4FA5-94BE-9054A631D2AC Q47419424-84D38E51-62C2-4D58-8FA9-FFE40E555316 Q47965968-2B279FAB-134A-482D-A75B-4D8B9E18C235 Q50112937-ADC441CA-A7C4-4D48-8ABD-C34372B9102E Q51546513-EAB8AF54-917B-4B95-A187-844808A403CD Q53117938-ECA8AB38-4185-402A-850A-4600D4181B08 Q55384042-BFCA397F-DD8B-4944-8FAA-B6FF8D08DE44 Q57049370-42B489AA-B40C-4CDD-ACDF-93CB76A1E1EF Q58605622-7FB6428A-6634-4559-9F54-2700866E5C6A Q58700818-7E89372C-F347-447E-A37E-964438BCD1C3 Q58767839-98CC2278-45C1-4D25-805C-39EAF68CDAC8

P2860

Clinical experience with Zarzio® in Europe: what have we learned?

http://www.wikidata.org/entity/Q38125609

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical experience with Zarzio® in Europe: what have we learned?

@en

type

label

Clinical experience with Zarzio® in Europe: what have we learned?

@en

prefLabel

Clinical experience with Zarzio® in Europe: what have we learned?

@en

P1433

Q38125609-41E82A95-A756-4E97-A010-E456C1E3D6C7

P1476

Q38125609-E613374F-0D55-46BC-9242-709E61A3CBB0

P2093

Q38125609-200570A6-C52B-4290-AB7D-48348B97EDAC

Q38125609-43E79A6E-2B5B-4454-BD3F-7BB52D483D37

Q38125609-5327CD91-911C-4B15-85EF-241669135D43

Q38125609-6E95C6DB-CFBA-47B8-8938-124B97F3A11C

Q38125609-8DD11D20-70FB-447D-A2C2-8C8623D3E81D

Q38125609-CF7D2F63-F470-442F-97DF-D4023B4ECAD8

Q38125609-F273D541-9C9F-47BC-90D2-815962016DF4

Q38125609-F28187A8-91A3-498D-8A99-F0A68174509D

Q38125609-F561118E-E8C6-4948-97BC-61DA5EA88EEA

Q38125609-FBE7D161-8128-4F26-B1E1-F8242048F55A

P2860

Q38125609-0A7BA33F-8815-4CD8-A677-1E83439CAE97

Q38125609-1AE292BA-F26F-4388-9DF3-722F66893674

Q38125609-1C54A7F8-2C8C-451A-B1FC-35FD4E2494C7

Q38125609-2828F913-5B80-4092-B7B8-BB7AD8537EF5

Q38125609-34C33E77-074C-4448-A44A-075D213D4603

Q38125609-5067A65D-193E-48CD-AEF8-FB61800E7995

Q38125609-58AAAB7B-69F4-4CBF-B146-7F8CC7B3F966

Q38125609-61F55E1A-34F0-4ECB-9DD9-C4EF869525A1

Q38125609-654548C3-E4D1-45CD-8788-196D2544C5D8

Q38125609-66B675A3-556C-4D44-B539-C274DEDC3788

P2888

Q38125609-54A88523-7E79-40A0-BC87-6A7FB7CE4C78

P304

Q38125609-D5C239C9-76D1-4288-A008-06DCB4C7D86B

P31

Q38125609-941DF3AF-62E0-4A4E-B808-6D822263A0A5

Q38125609-E506CFB0-5F51-4430-BFE9-97957ABCAC36

P356

Q38125609-9C9B3E16-A99C-443B-B682-21AF23D01AA6

P433

Q38125609-AEF69DDE-768D-4A6D-94D9-958756241122

P478

Q38125609-5B2A6221-03F9-470C-BF77-03810306D4BC

P577

Q38125609-2548D30D-46EA-4C74-AB44-490DF46951D3

Q38125609-EE6019A0-F776-4299-8C56-DE2B0F91E424

P5875

Q38125609-7F30FA8D-EDF6-417A-BF00-B9EC5587AE07

P698

Q38125609-0607E288-F554-48BD-B355-636CD2BA4487

P921

Q38125609-4B1408D6-511B-45AA-BFD4-A25DBEA16AD4

Q38125609-C4AABF99-6B19-4323-8764-59AA96BE3B1C

P932

Q38125609-C30B2939-0902-4F0E-ADA8-7E72643FD616

P356

S00520-013-1911-7

P1433

Supportive Care in Cancer

P1476

Clinical experience with Zarzio® in Europe: what have we learned?

@en

P2093

Hans Tesch

http://www.w3.org/2001/XMLSchema#string

Helen Barker

http://www.w3.org/2001/XMLSchema#string

Karl Verpoort

http://www.w3.org/2001/XMLSchema#string

Maria Sofia Rosati

http://www.w3.org/2001/XMLSchema#string

Matthew Turner

http://www.w3.org/2001/XMLSchema#string

Michael Muenzberg

http://www.w3.org/2001/XMLSchema#string

Nello Salesi

http://www.w3.org/2001/XMLSchema#string

Nils Wilking

http://www.w3.org/2001/XMLSchema#string

Pere Gascón

http://www.w3.org/2001/XMLSchema#string

Samir Agrawal

http://www.w3.org/2001/XMLSchema#string

P2860

Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product.

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Biosimilar agents in oncology/haematology: from approval to practice

The economic pressures for biosimilar drug use in cancer medicine

A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre.

The challenge of biosimilars.

Biosimilar drugs : concerns and opportunities.

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

P2888

s00520-013-1911-7

P304

2925-2932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-013-1911-7

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

254261100

http://www.w3.org/2001/XMLSchema#string

P698

23903799

http://www.w3.org/2001/XMLSchema#string

P921

P932

3765845

http://www.w3.org/2001/XMLSchema#string